Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043458750> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2043458750 endingPage "A479" @default.
- W2043458750 startingPage "A479" @default.
- W2043458750 abstract "To evaluate the affordability of switching patients already treated with the multi-pill therapy of simvastatin and fenofibrate to the first simvastatin and fenofibrate fixed dosed combinations (FDC) product, for the management of mixed dyslipidemia in the Greek health care setting. A budget impact model was locally adapted. The analysis was conducted from a third-party payer perspective over a time horizon of 3 years. The population with mixed dyslipidemia in Greece, the market shares of available treatments and the corresponding drug acquisition costs were combined to estimate the total budgetary impact that will result from the penetration of FDC in the Greek market. Data on population with mixed dyslipidemia were derived from the National Statistical Service and published literature. Estimates of the current and future market shares were obtained from Abbott Hellas market research. Drug acquisition costs were calculated using the latest price bulletin issued and the corresponding reimbursement prices. Reimbursement prices were reduced by the patient’s relevant co-payment and relative rebates. Since market prices for the FDC are not available yet in Greece, estimated retail prices provided by Abbott Hellas were considered [FDC 20/145: €13.70 (€12.22-16.27) and FDC 40/145: €16.71 (€15.22-19.23) ]. Savings in pharmaceutical reimbursement on year 1 were estimated at 146,974 (€181,084-€88,503) decreasing the relevant cost by 5.87% (7.23%-3.53%). On year 2, savings of €250,544 (€322,536-€136,474) were attributed to the penetration of FDC, lowering the budget by 9.93% (12.78%-5.41%). On the 3rdyear, savings were estimated at €403,405 (€509,489-€221,565) reducing spending by 15.82% (19.98%-8.69%). On average, over the 3-year time horizon of the analysis, the addition of FDC was found to decrease reimbursement costs by 10.54% (13.33%-5.88%) generating savings of €266,974 (337,703€-€148,147). The introduction of FDC reimbursement will result in a predictable budget impact which is expected to decrease the relevant pharmaceutical cost for national health insurance." @default.
- W2043458750 created "2016-06-24" @default.
- W2043458750 creator A5014525409 @default.
- W2043458750 creator A5048911584 @default.
- W2043458750 creator A5059315181 @default.
- W2043458750 date "2014-11-01" @default.
- W2043458750 modified "2023-10-14" @default.
- W2043458750 title "Simvastatin Plus Fenofibrate As A Fixed Dose Combination In The Treatment Of Mixed Dyslipidemia In Greece: Budget Impact Analysis" @default.
- W2043458750 doi "https://doi.org/10.1016/j.jval.2014.08.1385" @default.
- W2043458750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27201394" @default.
- W2043458750 hasPublicationYear "2014" @default.
- W2043458750 type Work @default.
- W2043458750 sameAs 2043458750 @default.
- W2043458750 citedByCount "0" @default.
- W2043458750 crossrefType "journal-article" @default.
- W2043458750 hasAuthorship W2043458750A5014525409 @default.
- W2043458750 hasAuthorship W2043458750A5048911584 @default.
- W2043458750 hasAuthorship W2043458750A5059315181 @default.
- W2043458750 hasBestOaLocation W20434587501 @default.
- W2043458750 hasConcept C10138342 @default.
- W2043458750 hasConcept C126322002 @default.
- W2043458750 hasConcept C144133560 @default.
- W2043458750 hasConcept C16051113 @default.
- W2043458750 hasConcept C160735492 @default.
- W2043458750 hasConcept C162324750 @default.
- W2043458750 hasConcept C2776329913 @default.
- W2043458750 hasConcept C2776623344 @default.
- W2043458750 hasConcept C2778096610 @default.
- W2043458750 hasConcept C2778110834 @default.
- W2043458750 hasConcept C2779703844 @default.
- W2043458750 hasConcept C2908647359 @default.
- W2043458750 hasConcept C50522688 @default.
- W2043458750 hasConcept C511355011 @default.
- W2043458750 hasConcept C71924100 @default.
- W2043458750 hasConcept C99454951 @default.
- W2043458750 hasConceptScore W2043458750C10138342 @default.
- W2043458750 hasConceptScore W2043458750C126322002 @default.
- W2043458750 hasConceptScore W2043458750C144133560 @default.
- W2043458750 hasConceptScore W2043458750C16051113 @default.
- W2043458750 hasConceptScore W2043458750C160735492 @default.
- W2043458750 hasConceptScore W2043458750C162324750 @default.
- W2043458750 hasConceptScore W2043458750C2776329913 @default.
- W2043458750 hasConceptScore W2043458750C2776623344 @default.
- W2043458750 hasConceptScore W2043458750C2778096610 @default.
- W2043458750 hasConceptScore W2043458750C2778110834 @default.
- W2043458750 hasConceptScore W2043458750C2779703844 @default.
- W2043458750 hasConceptScore W2043458750C2908647359 @default.
- W2043458750 hasConceptScore W2043458750C50522688 @default.
- W2043458750 hasConceptScore W2043458750C511355011 @default.
- W2043458750 hasConceptScore W2043458750C71924100 @default.
- W2043458750 hasConceptScore W2043458750C99454951 @default.
- W2043458750 hasIssue "7" @default.
- W2043458750 hasLocation W20434587501 @default.
- W2043458750 hasLocation W20434587502 @default.
- W2043458750 hasOpenAccess W2043458750 @default.
- W2043458750 hasPrimaryLocation W20434587501 @default.
- W2043458750 hasRelatedWork W1760447829 @default.
- W2043458750 hasRelatedWork W1992908766 @default.
- W2043458750 hasRelatedWork W2043458750 @default.
- W2043458750 hasRelatedWork W2081721069 @default.
- W2043458750 hasRelatedWork W2346161482 @default.
- W2043458750 hasRelatedWork W2372283311 @default.
- W2043458750 hasRelatedWork W2378491861 @default.
- W2043458750 hasRelatedWork W2378812482 @default.
- W2043458750 hasRelatedWork W2588374583 @default.
- W2043458750 hasRelatedWork W4301873265 @default.
- W2043458750 hasVolume "17" @default.
- W2043458750 isParatext "false" @default.
- W2043458750 isRetracted "false" @default.
- W2043458750 magId "2043458750" @default.
- W2043458750 workType "article" @default.